Skip to main content
Top
Published in: Journal of General Internal Medicine 12/2013

01-12-2013 | Original Research

Weight Loss Success in Metabolic Syndrome by Telephone Interventions: Results from the SHINE Study

Authors: Ruth S. Weinstock, MD, PhD, Paula M. Trief, PhD, Donald Cibula, PhD, Philip C. Morin, MS, Linda M. Delahanty, MS, RD

Published in: Journal of General Internal Medicine | Issue 12/2013

Login to get access

ABSTRACT

BACKGROUND

The Diabetes Prevention Program (DPP) intensive lifestyle intervention resulted in significant weight loss, reducing the development of diabetes, but needs to be adapted to primary care provider (PCP) practices.

OBJECTIVES

To compare a DPP-translation using individual (IC) vs. conference (CC) calls delivered by PCP staff for the outcome of percent weight loss over 2 years.

DESIGN

Randomized clinical trial.

SETTING

Five PCP sites.

PARTICIPANTS

Obese patients with metabolic syndrome, without diabetes (IC, n = 129; CC, n = 128).

INTERVENTION

Telephone delivery of the DPP Lifestyle Balance intervention [16-session core curriculum in year 1, 12-session continued telephone contact in year 2 plus telephone coaching sessions (dietitians).

MAIN MEASURES

Weight (kg), body mass index (BMI), and waist circumference.

KEY RESULTS

Baseline data: age = 52 years, BMI = 39 kg/m2, 75 % female, 85 % non-Hispanic White, 13 % non-Hispanic Black, and 48 % annual incomes <$40,000/year. In the intention-to-treat analyses at year 2, mean percent weight loss was −5.6 % (CC, p < 0.001) and −1.8 % (IC, p = 0.046) and was greater for CC than for IC (p = 0.016). At year 2, mean weight loss was 6.2 kg (CC) and 2.2 kg (IC) (p < 0.001). There was similar weight loss at year 1, but between year 1 and year 2 CC participants continued to lose while IC participants regained. At year 2, 52 % and 43 % (CC) and 29 % and 22 % (IC) of participants lost at least 5 % and 7 % of initial weight. BMI also decreased more for CC than IC (−2.1 kg/m2 vs. −0.8 kg/m2 p < 0.001). Waist circumference decreased by 3.1 cm (CC) and 2.4 cm (IC) at year 2. Completers (≥9 of 16 sessions; mean 13.3 sessions) lost significantly more weight than non-completers (mean 4.3 sessions).

CONCLUSIONS

PCP staff delivery of the DPP lifestyle intervention by telephone can be effective in achieving weight loss in obese people with metabolic syndrome. Greater weight loss may be attained with a group telephone intervention.
Literature
1.
go back to reference Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34:216–219.PubMedCrossRef Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34:216–219.PubMedCrossRef
2.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, for the Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE, for the Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRef
3.
go back to reference Knowler WC, Fowler SE, Hamman RF, for the Diabetes Prevention Program Research Group, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.PubMedCrossRef Knowler WC, Fowler SE, Hamman RF, for the Diabetes Prevention Program Research Group, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.PubMedCrossRef
4.
go back to reference Herman WH, Brandle M, Zhang P, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36–47.CrossRef Herman WH, Brandle M, Zhang P, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36–47.CrossRef
5.
go back to reference Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619.PubMedCrossRef Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619.PubMedCrossRef
6.
go back to reference Ali MK, Echouffo-Tcheugui JB, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Affairs. 2012;31:67–75.PubMedCrossRef Ali MK, Echouffo-Tcheugui JB, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Affairs. 2012;31:67–75.PubMedCrossRef
7.
go back to reference Katula JA, Vitolins MZ, Rosenberger CS, et al. One-year results of a community-based translation of the Diabetes Prevention Program. Healthy-living partnerships to prevent diabetes (HELP PD) project. Diabetes Care. 2011;34:1451–1457.PubMedCrossRef Katula JA, Vitolins MZ, Rosenberger CS, et al. One-year results of a community-based translation of the Diabetes Prevention Program. Healthy-living partnerships to prevent diabetes (HELP PD) project. Diabetes Care. 2011;34:1451–1457.PubMedCrossRef
8.
go back to reference Ackermann RT, Finch EA, Caffrey HM, et al. Long-term effects of a community-based lifestyle intervention to prevent type 2 diabetes: the DEPLOY extension pilot study. Chronic illness. 2011;7:279–290.PubMedCrossRef Ackermann RT, Finch EA, Caffrey HM, et al. Long-term effects of a community-based lifestyle intervention to prevent type 2 diabetes: the DEPLOY extension pilot study. Chronic illness. 2011;7:279–290.PubMedCrossRef
9.
go back to reference Boltri JM, Davis-Smith M, Okosun IS, et al. Translation of the National Institutes of Health Diabetes Prevention Program in African American churches. J Natl Med Assoc. 2011;103:194–202.PubMed Boltri JM, Davis-Smith M, Okosun IS, et al. Translation of the National Institutes of Health Diabetes Prevention Program in African American churches. J Natl Med Assoc. 2011;103:194–202.PubMed
11.
go back to reference Smith AW, Borowski LA, Liu B, et al. US primary care physicians’ diet-, physical activity-, and weight-related care of adult patients. Am J Prev Med. 2011;41:33–42.PubMedCrossRef Smith AW, Borowski LA, Liu B, et al. US primary care physicians’ diet-, physical activity-, and weight-related care of adult patients. Am J Prev Med. 2011;41:33–42.PubMedCrossRef
12.
go back to reference Ross R, Lam L, Blair SN, et al. Trial of prevention and reduction of obesity through active living in clinical settings: A randomized controlled trial. Arch Intern Med. 2012;172:414–424.PubMedCrossRef Ross R, Lam L, Blair SN, et al. Trial of prevention and reduction of obesity through active living in clinical settings: A randomized controlled trial. Arch Intern Med. 2012;172:414–424.PubMedCrossRef
13.
go back to reference Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med. 2011;365:1969–1979.PubMedCrossRef Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med. 2011;365:1969–1979.PubMedCrossRef
14.
go back to reference Kushner RF. Barriers to providing nutrition counseling by physicians: A survey of primary care practitioners. Prev Med. 1995;24:546–552.PubMedCrossRef Kushner RF. Barriers to providing nutrition counseling by physicians: A survey of primary care practitioners. Prev Med. 1995;24:546–552.PubMedCrossRef
15.
go back to reference Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med. 2009;24:1073–1079.PubMedCrossRef Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med. 2009;24:1073–1079.PubMedCrossRef
16.
go back to reference Ciao AC, Latner JD, Durso LE. Treatment seeking and barriers to weight loss treatments of different intensity levels among obese and overweight individuals. Eating and Weight Disorders. 2012;17:e9–16.PubMedCrossRef Ciao AC, Latner JD, Durso LE. Treatment seeking and barriers to weight loss treatments of different intensity levels among obese and overweight individuals. Eating and Weight Disorders. 2012;17:e9–16.PubMedCrossRef
17.
go back to reference Renjilian DA, Perri MG, Nezu AM, et al. Individual vs. group therapy for obesity: Effects of matching participants to their treatment preference. J Consult Clin Psychol. 2001;69:717–721.PubMedCrossRef Renjilian DA, Perri MG, Nezu AM, et al. Individual vs. group therapy for obesity: Effects of matching participants to their treatment preference. J Consult Clin Psychol. 2001;69:717–721.PubMedCrossRef
18.
go back to reference Cresci B, Tesi F, La Ferlita T, Ricca V, et al. Group versus individual cognitive-behavioral treatment for obesity: Results after 36 months. Eat Weight Disord. 2007;12:147–153.PubMedCrossRef Cresci B, Tesi F, La Ferlita T, Ricca V, et al. Group versus individual cognitive-behavioral treatment for obesity: Results after 36 months. Eat Weight Disord. 2007;12:147–153.PubMedCrossRef
19.
go back to reference Befort CA, Donnelly JE, Sullivan DK, et al. Group versus individual phone-based obesity treatment for rural women. Eating Behaviors. 2010;11:11–17.PubMedCrossRef Befort CA, Donnelly JE, Sullivan DK, et al. Group versus individual phone-based obesity treatment for rural women. Eating Behaviors. 2010;11:11–17.PubMedCrossRef
20.
go back to reference The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care. 2002;25:2165–2171.CrossRef The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care. 2002;25:2165–2171.CrossRef
21.
go back to reference Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–1062.PubMedCrossRef Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–1062.PubMedCrossRef
22.
go back to reference Williamson DF, Marrero DG. Scaling up type 2 diabetes prevention programs for high risk persons: progress and challenges in the United States. In: Schwarz P, Reddy P, Greaves C, Dunbar JA, Schwarz J, eds. Diabetes prevention in practice. Dresden: TIMAINI Institute for Prevention Management; 2010:69–82. Williamson DF, Marrero DG. Scaling up type 2 diabetes prevention programs for high risk persons: progress and challenges in the United States. In: Schwarz P, Reddy P, Greaves C, Dunbar JA, Schwarz J, eds. Diabetes prevention in practice. Dresden: TIMAINI Institute for Prevention Management; 2010:69–82.
23.
go back to reference The Diabetes Prevention Program Research Group. Baseline characteristics of the randomized cohort. Diabetes Care. 2000;23:1619–1629.CrossRef The Diabetes Prevention Program Research Group. Baseline characteristics of the randomized cohort. Diabetes Care. 2000;23:1619–1629.CrossRef
24.
go back to reference Appel LJ, Clark JM, Yeh H-C, et al. Comparative effectiveness in weight-loss interventions in clinical practice. N Engl J Med. 2011;365:1959–1968.PubMedCrossRef Appel LJ, Clark JM, Yeh H-C, et al. Comparative effectiveness in weight-loss interventions in clinical practice. N Engl J Med. 2011;365:1959–1968.PubMedCrossRef
25.
go back to reference Bennett GG, Warner ET, Glasgow RE, et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. Arch Intern Med. 2012;172:565–574.PubMedCrossRef Bennett GG, Warner ET, Glasgow RE, et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. Arch Intern Med. 2012;172:565–574.PubMedCrossRef
26.
go back to reference Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: A starting point for continuous improvement. Brit J Gen Pract. 2008;58:548–554.CrossRef Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: A starting point for continuous improvement. Brit J Gen Pract. 2008;58:548–554.CrossRef
Metadata
Title
Weight Loss Success in Metabolic Syndrome by Telephone Interventions: Results from the SHINE Study
Authors
Ruth S. Weinstock, MD, PhD
Paula M. Trief, PhD
Donald Cibula, PhD
Philip C. Morin, MS
Linda M. Delahanty, MS, RD
Publication date
01-12-2013
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 12/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2529-7

Other articles of this Issue 12/2013

Journal of General Internal Medicine 12/2013 Go to the issue

Healing Arts

The Mentor

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine